Abstract:Background: Cardiac hypertrophy is an important prepathology of, and will ultimately lead to, heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. This study aims to elucidate the effects and mechanisms of HINT1 (histidine triad nucleotide-binding protein 1) in cardiac hypertrophy and heart failure. Methods: HINT1 was downregulated in human hypertrophic heart samples compared with nonhypertrophic samples by mass spectrometry analysis. Hint1 knockout mice were challenged with transverse aortic constriction surgery. Cardiac-specific overexpression of HINT1 mice by intravenous injection of adeno-associated virus 9 (AAV9)-encoding Hint1 under the cTnT (cardiac troponin T) promoter were subjected to transverse aortic construction. Unbiased transcriptional analyses were used to identify the downstream targets of HINT1. AAV9 bearing shRNA against Hoxa5 (homeobox A5) was administrated to investigate whether the effects of HINT1 on cardiac hypertrophy were HOXA5-dependent. RNA sequencing analysis was performed to recapitulate possible changes in transcriptome profile.Coimmunoprecipitation assays and cellular fractionation analyses were conducted to examine the mechanism by which HINT1 regulates the expression of HOXA5. Results: The reduction of HINT1 expression was observed in the hearts of hypertrophic patients and pressure overloaded-induced hypertrophic mice, respectively. In Hint1-deficient mice, cardiac hypertrophy deteriorated after transverse aortic construction. Conversely, cardiac-specific overexpression of HINT1 alleviated cardiac hypertrophy and dysfunction. Unbiased profiler polymerase chain reaction array showed HOXA5 is 1 target for HINT1, and the cardioprotective role of HINT1 was abolished by HOXA5 knockdown in vivo. Hoxa5 was identified to affect hypertrophy through the TGF-beta (transforming growth factor beta) signal pathway. Mechanically, HINT1 inhibited PKC beta 1 (protein kinase C beta type 1) membrane translocation and phosphorylation via direct interaction, attenuating the MEK/ERK/YY1 (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/yin yang 1) signal pathway, downregulating HOXA5 expression, and eventually attenuating cardiac hypertrophy. Conclusions: HINT1 protects against cardiac hypertrophy through suppressing HOXA5 expression. These findings indicate that HINT1 may be a potential target for therapeutic interventions in cardiac hypertrophy and heart failure.

CKIP-1 Inhibits Cardiac Hypertrophy by Regulating Class II Histone Deacetylase Phosphorylation Through Recruiting PP2A.

Casein Kinase-2 Interacting Protein-1 Regulates Physiological Cardiac Hypertrophy via Inhibition of Histone Deacetylase 4 Phosphorylation

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBPβ Axis

Kchip2 Attenuates Cardiac Hypertrophy Through Regulation of Ito

Cip, A Cardiac Isl1-Interacting Protein, Represses Cardiomyocyte Hypertrophy

Hint1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing Hoxa5 (Homeobox A5) Expression

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Abstract 65: Regulation of Cardiac Hypertrophy and Dilated Cardiomyopathy by CIP

Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure

Cardiomyocyte-Enriched Protein Cip Protects Against Pathophysiological Stresses And Regulates Cardiac Homeostasis

3′ untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload

Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy

CKIP-1 Limits Foam Cell Formation and Inhibits Atherosclerosis by Promoting Degradation of Oct-1 by REGγ

Cardiac-specific BACH1 Ablation Attenuates Pathological Cardiac Hypertrophy by Inhibiting the Ang II Type 1 Receptor Expression and the Ca2+/CaMKII Pathway.

Histidine Triad Nucleotide Binding Protein 1 Attenuates Cardiac Hypertrophy via Suppressing Homeobox A5 Expression

Pak1 As A Novel Therapeutic Target for Antihypertrophic Treatment in the Heart

Pka Phosphorylates Histone Deacetylase 5 and Prevents Its Nuclear Export, Leading to the Inhibition of Gene Transcription and Cardiomyocyte Hypertrophy

IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.